The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Clinical targeting of HIV capsid protein with a long-acting small molecule
Open accessAbstract
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis1–5. However, some people living with HIV who are heavily treatment-experienced have limited or no treatment options, owing to multidrug resistance6. In addition, suboptimal adherence to oral daily regimens can negatively affect the outcome of treatment—which contributes to virologic failure, resistance generation and viral transmission—as well as of pre-exposure prophylaxis, leading to new infections1,2,4,7–9. Long-acting agents from new antiretroviral classes can provide much-needed treatment options for people living with HIV who are heavily treatment-experienced, and additionally can improve adherence10. Here we describe GS-6207, a small molecule that disrupts the functions of HIV capsid protein and is amenable to long-acting therapy owing to its high potency, low in vivo systemic clearance and slow release kinetics from the subcutaneous injection site. Drawing on X-ray crystallographic information, we designed GS-6207 to bind tightly at a conserved interface between capsid protein monomers, where it interferes with capsid-protein-mediated interactions between proteins that are essential for multiple phases of the viral replication cycle. GS-6207 exhibits antiviral activity at picomolar concentrations against all subtypes of HIV-1 that we tested, and shows high synergy and no cross-resistance with approved antiretroviral drugs. In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (450 mg) resulted in a mean log10-transformed reduction of plasma viral load of 2.2 after 9 days, and showed sustained plasma exposure at antivirally active concentrations for more than 6 months. These results provide clinical validation for therapies that target the functions of HIV capsid protein, and demonstrate the potential of GS-6207 as a long-acting agent to treat or prevent infection with HIV. The small molecule GS-6207, which disrupts the function of the HIV capsid protein, shows potential as a long-acting therapeutic agent for the treatment and prevention of HIV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C., Le Gall, J.-M., Cua, E., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,633
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationTenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya-Herrera, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,020
Cited by
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407001 · Cited by 523
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Segal-Maurer, S., DeJesus, E., Stellbrink, H.-J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., Wang, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115542 · Cited by 331
Self-citationReconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro
Christensen, D. E., Ganser-Pornillos, B. K., Johnson, J. S., Pornillos, O., & Sundquist, W. I. (2020) · Science · doi:10.1126/science.abc8420 · Cited by 150
Self-citationHIV capsid and integration targeting
Engelman, A. N. (2021) · Viruses · doi:10.3390/v13010125 · Cited by 57
Troyano-Hernáez, P., Reinosa, R., & Holguín, Á. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.854974 · Cited by 48
Metadata
- Authors
- Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A., Hansen, D., Singer, E., Tsai, L. K., Bam, R. A., Chou, C.-H., Canales, E., Brizgys, G., Zhang, J. R., Li, J., Graupe, M., Morganelli, P., Liu, Q., Wu, Q., Halcomb, R. L., Saito, R. D., Schroeder, S. D., Lazerwith, S. E., Bondy, S., Jin, D., Hung, M., Novikov, N., Liu, X., Villaseñor, A. G., Cannizzaro, C. E., Hu, E. Y., Anderson, R. L., Appleby, T. C., Lu, B., Mwangi, J., Liclican, A., Niedziela-Majka, A., Papalia, G. A., Wong, M. H., Leavitt, S. A., Xu, Y., Koditek, D., Stepan, G. J., Yu, H., Pagratis, N., Clancy, S., Ahmadyar, S., Cai, T. Z., Sellers, S., Wolckenhauer, S. A., Ling, J., Callebaut, C., Margot, N., Ram, R. R., Liu, Y.-P., Hyland, R., Sinclair, G. I., Ruane, P. J., Crofoot, G. E., McDonald, C. K., Brainard, D. M., Lad, L., Swaminathan, S., Sundquist, W. I., Sakowicz, R., Chester, A. E., Lee, W. E., Daar, E. S., Yant, S. R., & Cihlar, T.
- Venue
- Nature
- Published
- 2020-07-01
- Volume
- 584
- Issue
- 7822
- Pages
- 614-618
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3040374393
- Cited by
- 425
- References
- 39
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical targeting of HIV capsid protein with a long-acting small molecule. https://app.cochat.ai/papers/10.1038/s41586-020-2443-1
- The paper
- Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A., Hansen, D., Singer, E., Tsai, L. K., Bam, R. A., Chou, C.-H., Canales, E., Brizgys, G., Zhang, J. R., Li, J., Graupe, M., . . . Cihlar, T. (2020). Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. https://doi.org/10.1038/s41586-020-2443-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.